Epigral Limited Earnings Summary — Q4 FY2026
Epigral Reports Strong Revenue Recovery in Q4; Sequential Profit Rebound Amid Margin Pressure
Quarterly Business Intelligence
AI Quarterly Scorecard™
Computed deterministically from the last 10 reported quarters.
Quarterly Business Momentum
- Revenue declined 4.2% sequentially in Q1 FY2027.
- Revenue of ₹705 Cr is 16.3% higher year-on-year.
- Revenue has compounded at 14.1% annualised over the last 10 quarters.
- Net profit of ₹100 Cr is 37.9% below the same quarter last year.
- Profit growth is trailing revenue growth this quarter.
- Net profit has compounded at 12.0% annualised across the period.
- Operating margin stands at 25.4% in Q1 FY2027.
- Operating margin compressed by 153 bps year-on-year.
- Over the last two years operating margin has contracted by 166 bps.
- PBT margin is 19.0%.
- Expenses grew 18.7% against revenue growth of 16.3%.
- Operating profit of ₹179 Cr is 9.7% higher year-on-year.
- Operating leverage has been under pressure recently.
- 3 of the last 6 measured quarters delivered year-on-year revenue growth.
- Overall quarterly business momentum scores 60/100 (Healthy) on the latest 10 quarters.
- Business momentum has softened and warrants monitoring.
Quarterly Financials
Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %
| Metric | Trend | Latest Q1 FY2027 | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | Improving | 705 | 736 | 597 | 587 | 607 | 628 | 645 | 626 | 651 | 525 |
| Expenses | Improving | 526 | 569 | 494 | 455 | 443 | 454 | 463 | 448 | 475 | 369 |
| Operating Profit | Accelerating | 179 | 168 | 103 | 132 | 163 | 173 | 183 | 178 | 176 | 155 |
| Operating Margin | Stable | 25.4% | 22.8% | 17.2% | 22.5% | 26.9% | 27.6% | 28.3% | 28.5% | 27.1% | 29.6% |
| Other Income | Volatile | 5 | -1 | 6 | 2 | 9 | 4 | 4 | 6 | 2 | 2 |
| Interest | Volatile | 7 | 16 | 11 | 22 | 23 | 12 | -0 | 27 | 14 | 14 |
| Depreciation | Improving | 43 | 42 | 43 | 42 | 42 | 34 | 33 | 32 | 33 | 30 |
| Profit Before Tax | Accelerating | 134 | 110 | 55 | 70 | 107 | 131 | 154 | 125 | 131 | 113 |
| Tax | Volatile | 34 | 29 | 15 | 18 | -54 | 44 | 50 | 44 | 45 | 36 |
| Net Profit | Volatile | 100 | 81 | 39 | 51 | 161 | 87 | 104 | 81 | 86 | 77 |
| Net Margin | Volatile | 14.1% | 11.0% | 6.5% | 8.7% | 26.5% | 13.8% | 16.1% | 13.0% | 13.2% | 14.7% |
Key Takeaways
- Revenue reached a multi-quarter high of ₹736 Cr in Q4 FY2026, up 17% YoY and 23% QoQ.
- Net profit saw a sharp sequential recovery from ₹39 Cr to ₹81 Cr, although it remained below the peak FY25 levels.
- Operating margins show signs of stabilization at 23% after bottoming out at 17% in the previous quarter.
- The balance sheet remains healthy with total borrowings reduced significantly to ₹572 Cr from ₹964 Cr two years prior.
- The product mix is evolving, with specialty derivatives now projected to constitute over 50% of the revenue mix.
- Working capital efficiency faced headwinds as debtor days increased to 60 days compared to 33 days in the previous year.
Management Guidance
Management is focused on transitioning from commodity-heavy Chlor-Alkali to high-value derivatives like CPVC resin and Epichlorohydrin to mitigate industry cyclicality.
Sentiment Shift
Improving
While YoY profitability and margins are down, the sharp sequential rebound in revenue and PAT suggests the company has passed the trough of the current cycle.
Outlook
The outlook is cautiously optimistic as new project commissions (CPVC, ECH) start contributing significantly to the mix, though global chemical pricing remains a monitorable risk.
From the Annual Report (Key Quotes)
“The business has successfully transitioned from a commodity-heavy portfolio to high-value derivatives.”
“Execution has been reliable, with multiple complex chemical units commissioned on or near schedule.”
“Margins have faced pressure due to raw material costs and global pricing trends.”
Official Quarterly Documents
This summary is AI-generated from Epigral Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.